At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
XFOR X4 Pharmaceuticals Inc
Market Closed 07-17 16:00:00 EDT
3.82
-0.01
-0.26%
盘后3.82
+0.000.00%
16:10 EDT
High3.85Low3.70Vol461.94K
Open3.73D1 Closing3.83Amplitude3.92%
Mkt Cap360.30MTradable Cap259.57MTotal Shares94.32M
T/O1.75MT/O Rate0.68%Tradable Shares67.95M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

X4 Pharmaceuticals Inc : Wells Fargo Initiates Coverage with Overweight Rating; Price Target $11
THOMSON REUTERS  ·  07-10
X4 Pharmaceuticals Inc : Wells Fargo Initiates Coverage with Overweight Rating; Price Target $11
X4 Pharmaceuticals Issues Inducement Stock Options for 750,000 Shares at $4.03 Each
Reuters  ·  07-08
X4 Pharmaceuticals Issues Inducement Stock Options for 750,000 Shares at $4.03 Each
X4 Pharmaceuticals Director Kelly Gold Files Initial Beneficial Ownership Statement
Reuters  ·  07-02
X4 Pharmaceuticals Director Kelly Gold Files Initial Beneficial Ownership Statement
Press Release: X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to Its Board of Directors
Dow Jones  ·  07-01
Press Release: X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to Its Board of Directors
X4 Pharmaceuticals Initiated at Outperform by Leerink Partners
Dow Jones  ·  06-02
X4 Pharmaceuticals Initiated at Outperform by Leerink Partners
X4 Pharmaceuticals initiated with an Outperform at Leerink
TIPRANKS  ·  06-02
X4 Pharmaceuticals initiated with an Outperform at Leerink
X4 Pharmaceuticals Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $12
THOMSON REUTERS  ·  06-02
X4 Pharmaceuticals Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $12
U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik
Reuters  ·  06-02
U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik
BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
Reuters  ·  06-02
BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule
X4 Pharmaceuticals grants 160,000 inducement stock options priced at $4.31 per share
Reuters  ·  06-02
X4 Pharmaceuticals grants 160,000 inducement stock options priced at $4.31 per share
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
THOMSON REUTERS  ·  06-02
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
X4 Pharma to present at Jefferies Global Healthcare Conference
Reuters  ·  05-27
X4 Pharma to present at Jefferies Global Healthcare Conference
X4 Pharmaceuticals corrects director nominee name in amended 8-K filing
Reuters  ·  05-14
X4 Pharmaceuticals corrects director nominee name in amended 8-K filing
X4 Pharmaceuticals shareholders approved amended 2017 equity incentive plan share increase
Reuters  ·  05-13
X4 Pharmaceuticals shareholders approved amended 2017 equity incentive plan share increase
BRIEF-X4 Pharmaceuticals Inc - May Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or Units - SEC Filing
Reuters  ·  05-07
BRIEF-X4 Pharmaceuticals Inc - May Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or Units - SEC Filing
X4 Pharmaceuticals Inc - May Offer up to $300 Mln of Common Stock, Preferred Stock, Debt Securities, Warrants, and/or Units - SEC Filing
THOMSON REUTERS  ·  05-07
X4 Pharmaceuticals Inc - May Offer up to $300 Mln of Common Stock, Preferred Stock, Debt Securities, Warrants, and/or Units - SEC Filing
X4 Pharmaceuticals net loss widens to $20.2 million in Q1 FY26; revenue drops to $2.7 million
Reuters  ·  05-06
X4 Pharmaceuticals net loss widens to $20.2 million in Q1 FY26; revenue drops to $2.7 million
BRIEF-X4 Pharmaceuticals Q1 EPS USD -0.16
Reuters  ·  05-06
BRIEF-X4 Pharmaceuticals Q1 EPS USD -0.16
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
THOMSON REUTERS  ·  05-06
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
X4 Pharmaceuticals Q1 Operating Expenses USD 23.014 Million
THOMSON REUTERS  ·  05-06
X4 Pharmaceuticals Q1 Operating Expenses USD 23.014 Million

Introduction

Company Name.
X4 Pharmaceuticals Inc
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Issue price:
--